Coverage
-
August 29, 2013
Two special masters recommended Wednesday that a New Jersey federal court approve $140 million in attorneys' fees sought by class counsel who settled for $688 million two securities class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results on the efficacy of their anti-cholesterol drug Vytorin.
4 other articles on this case.
View all »